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Background/Introduction
The conventional glutaraldehyde (GA) fixation for cardiac
xenograft causes dystrophic calcification, and there is also
a significant immune reaction to the galactose-a-1,3 galac-
tose b-1,4-N-acetylglucosamine (a-Gal), leading to calcifi-
cation. So, future investigation should be redirected in the
quest for the aGal-free long-lasting substitutes.
Aims/Objectives
We made the aGal-free long-lasting stented valve which is
comprised of self-expanding nitinol frame containing
GA-fixed xenografts treated by our novel combined antic-
alcification protocol. The safety and efficacy of our stented
valve were evaluated using large-animal in vivo perventri-
cular pulmonic circulatory models.
Method
Porcine cardiac xenografts were treated by decellulariza-
tion, immunologic modification with alpha-galactosidase,
space filler, GA fixation in organic solvent, and detoxifica-
tion. The nitinol (Nikel-Titanium, shape memory alloy)
frame is comprised of a braided wire that reverts to its ori-
ginal shape and locks the valve into position as deployed.
We manufactured the stented valve with the porcine
cardiac xenografts mounted on a nitinol frame. The
stented valves were implanted in ovine pulmonary valve
position via perventricular approach, and durability was
evaluated for 18 months after implantation.
Results
To 18 months after perventricular pulmonic valve implan-
tation, evaluation of echocardiography and cardiac cathe-
terization demonstrated good hemodynamic status and
function of pulmonary valve, and good endothelialization
resulted in no paravalvular leakage. Durability of the
porcine cardiac xenografts was well preserved without
calcification.
Discussion/Conclusion
We demonstrated the safety and efficacy of the aGal-
free long-lasting stented valve with our synergistic and
simultaneous employment of multiple anticalcification
therapies including immunologic modification with
alpha-galactosidase. The future clinical study is warranted
based on these promising preclinical results using large-
animal in vivo perventricular pulmonic circulatory models.
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